Aetna Plans “Clinical Alert” On Plavix Use With PPIs Based On Claims Review
Aetna is developing a clinical alert for physicians and pharmacists to warn about potentially reduced effectiveness for Plavix (clopidogrel) when the antiplatelet drug is used concurrently with a proton pump inhibitor, such as Prilosec (omeprazole) or Nexium (esomeprazole)
You may also be interested in...
Takeda could position Kapidex as the proton pump inhibitor of choice if a new clinical trial confirms its interaction profile is more agreeable than other PPI products
Study of how several PPIs might affect the pharmacokinetics and pharmacodynamics of Plavix could impact formulary placement.
Genetics and concomitant PPI use are possible reasons for the anti-platelet drug’s reduced effectiveness in some patients, according to an FDA “Early Communication.”